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Safety and efficacy are the two major concerns for any 
drug  therapy.  Globally  clinical  research  plays  an 
inevitable role in bringing a new molecule into the market 
after  its  synthesis  by  the  pharmaceutical  industries. 
Availability of large patient population, highly educated 
and  skilled  manpower,  wide  spectrum  of  diseases  and 
favorable economic environment imply India’s potential 
as  a  global  hub  for  clinical  research.  Pharmaceutical 
companies  and  Clinical  Research  Organization  (CRO)s 
will  require  many  trained  personnel  to  carry  out  the 
clinical research. Keeping in mind these facts a CME with 
the  theme  of  “Clinical  research”  had  been  jointly 
organized  by  the  Dept  of  pharmacology,  K.L.E 
University’s  J.N.M.C,  Belgaum  and  Indian 
Pharmacological Society (I.P.S), Belgaum branch on 20th 
February  2010.  In  the  first  scientific  session, 
Dr.P.A.Patil (JNMC) spoke on “Preclinical studies”. In 
vitro and in vivo experiments of various doses of ‘study 
drug’  can  obtain  preliminary efficacy,  toxicity  and 
pharmacokinetic  information  suggesting  the  scientific 
merit for further development as an investigational new 
drug  (IND).  Local  or  systemic  toxicity  studies  can  be 
conducted (ex: urine analysis,  blood  biochemical assay, 
gross and microscopic pathology etc). Dr. B.J. Mahendra 
Kumar  (KLE  University’s  College  of  pharmacy)  talked 
on “Role of Drug Controller General of India (DCGI) in 
Clinical Trials”. He explained about Drug and cosmetic 
acts/rules,  requirements/guidelines  for  permission  to 
import and/or to manufacture new drugs or to undertake 
clinical trials i.e. Schedule Y and its appendices.  
 
Dr.N.M.Patil (JNMC) elaborated about “Ethical issues in 
clinical trials”. Ethics is required to: avoid exploitation of 
the  subjects  (maintain  safety  and  wellbeing),  protect 
vulnerable  groups,  children,  disabled,  elderly  etc. 
Independent  Ethics  Committees  (IEC)  and  Institutional 
Review Boards (IRB) are concerned with medical ethics. 
IECs review, regulate, monitor and supervise the clinical 
trials  or  the  research  projects.  Ethical  decision  is  taken 
without coercion, influence, inducement and intimidation. 
Dr.S.S.Torgal (JNMC) spoke on “Introduction to clinical 
trials”.  A  systematic  study  of  a  new  drug  in  human 
subjects to generate data for discovering and/or verifying 
the  clinical,  pharmacological  (pharmacodynamic  / 
pharmacokinetic)  and/or  adverse  effects  with  the 
objective of determining safety and/or efficacy of the new 
drug is known as clinical trial (Phase I, II, III and IV). 
There  are  many  types  of  trials  viz.,  Prevention  trials, 
Screening  trials,  Diagnostic  trials,  Treatment  trials, 
Quality  of life trials and Compassionate use trials.  The 
Clinical Trials Registry-India (CTRI) is an online register 
of clinical trials being conducted in India. 
 
In  the  second  scientific  session,  Dr.A.Shrivastav  (KLE 
Hospital)  talked  on  “Conducting  clinical  trials-
Investigators  perspective”.  He  explained  about  good 
clinical  practice,  role  of  primary  investigator,  CROs, 
DCGI,  site  management  office  (SMO),  regulatory 
requirements  and  data  management.  Essential  trial 
documents  include  protocol,  informed  consent  form, 
investigators brochure etc. Study team at site consists of 
investigator,  co/sub-investigator,  clinical  research/study 
coordinator,  research  nurse,  pharmacist,  unblinded 
personnel  etc.  Dr.S.I.Majagi  (JNMC)  gave  a  lecture  on 
“Pharmacovigilance”  which  is  a  science  of  activities 
relating to the detection, assessment, understanding and 
prevention of adverse drug reactions (ADR) or any other 
medicine  related  problem.  He  explained  about  history, 
need,  objectives,  applications,  methods  (spontaneous 
reports  etc),  organizations  involved  (WHO,  National 
pharmacovigilance center etc) in pharmacovigilance, Risk 
assessment, Risk management (RM), goals of RM, Risk 
minimization  action  plan(Risk  MAP),  tools  of  RM 
process  and  Signal:  detection,  sources,  data,  data 
interpretation,  selection  or  rejection,  strengthening  (by 
assessment  criteria),  reporting,  monitoring,  assessment 
and  follow  up.  He  enlightened  on  Good 
pharmacovigilance  practice,  PSUR  (Periodic  safety 
update  report),  case  report,  case  series  and 
pharmacovigilance  plans.  Dr.Tarun  Wadhwa  (JNMC) 
talked on “ADR monitoring and reporting”. He briefed 
about  predisposing  factors  and  classification  of  ADRs, 
adverse  events,  medication  errors,  preventable  events, 
ADR  reporting  system,  causality  assessment  criteria, 
severity assessment, WHO causality assessment scale and 
categories. More than 220 delegates from various medical 
colleges and other health institutions from Karnataka, Goa 
and  Maharashtra  participated  in  the  C.M.E.  In  the 
valedictory function, Dr.S.I.Majagi, Organizing secretary 
of  the  C.M.E  and  Secretary,  I.P.S,  Belgaum  branch 
proposed  vote  of  thanks  and  the  certificates  were 
distributed to the delegates. 
 